FollowTheFilings (@fdzmurillo) header
FollowTheFilings (@fdzmurillo) profile picture

Investor and researcher. I dig into SEC filings, patent courts, and buyback programs to find what corporations don't want you to see. When actions contradict wo

LONDON
Joined June 2009
Photo by FollowTheFilings (@fdzmurillo)Photo by FollowTheFilings (@fdzmurillo)Photo by FollowTheFilings (@fdzmurillo)Photo by FollowTheFilings (@fdzmurillo)Photo by FollowTheFilings (@fdzmurillo)Photo by FollowTheFilings (@fdzmurillo)Photo by FollowTheFilings (@fdzmurillo)Photo by FollowTheFilings (@fdzmurillo)Photo by FollowTheFilings (@fdzmurillo)Photo by FollowTheFilings (@fdzmurillo)
1
10
1,081
🚨🚀 $NVO — WEGOVY ORAL COULD BECOME ONE OF THE BIGGEST PHARMACEUTICAL BLOCKBUSTERS IN HISTORY! I believe Wall Street is massively underestimating what Novo Nordisk has created. THE NEXT NVIDIA OF PHARMACEUTICALS? THE KEY COULD BE SNAC TECHNOLOGY AND A DAILY PILL! Look at the latest results: 💊 6.2% WEIGHT LOSS IN JUST THREE MONTHS! Real-world data from 5,872 patients, achieved during dose escalation, before reaching the full 25 mg maintenance dose! ✅ 16.6% weight loss in OASIS 4 under the efficacy estimand. ❤️ FDA-approved cardiovascular risk reduction in eligible patients. ✅ Semaglutide has demonstrated remarkable benefits against MASH, with the approved liver indication currently applying to injectable Wegovy. 🧬 Promising research into biological aging, although longevity benefits remain unproven. THIS IS SO MUCH MORE THAN A WEIGHT-LOSS PILL! And now imagine the global demand. Christmas is coming. Millions of people will enter 2027 thinking about losing weight and improving their health. For eligible patients, there is now a proven daily oral treatment. NO INJECTIONS! HOW MANY PEOPLE WORLDWIDE WILL WANT THIS? Over ONE BILLION people live with obesity. Could the eventual market reach 100 MILLION patients? I believe that is entirely conceivable over the long term. But here's what REALLY excites me. 🔥 MY DECEMBER 2027 FORECAST: 🇺🇸 USA: 9.5 MILLION active patients. 🌍 Europe and other international markets: 4 MILLION. TOTAL: 13.5 MILLION ACTIVE PATIENTS. I assign an 80% probability to this aggressive scenario. Now let's calculate the REVENUE. I'm assuming a conservative average of just $200 PER PATIENT PER MONTH globally. Europe could potentially generate higher revenue per treatment, considering market competition, pricing and exchange rates. 13.5 MILLION PATIENTS × $200 = 💰💰 $2.7 BILLION IN MONTHLY REVENUE BY DECEMBER 2027! 🔥 $32.4 BILLION IN ANNUALISED REVENUE AT THAT EXIT RUN RATE! YES. REVENUE. NOT PROFIT. And this is just WEGOVY ORAL. Not injectable Wegovy. Not Ozempic. Not CagriSema. Not Novo's other businesses. Now imagine the long-term opportunity of 100 million patients at $200 per month: $20 BILLION IN POTENTIAL MONTHLY REVENUE. The enormous challenge? MANUFACTURING. My December 2027 scenario requires approximately 405 MILLION TABLETS EVERY MONTH! And that's why SNAC technology, protected oral formulations, manufacturing scale and global distribution matter so much. SNAC could be to oral peptide delivery what CUDA became to AI. MR DOUSTDAR, THIS IS YOUR MOMENT! Expand capacity. Secure supply. Accelerate worldwide availability. The UK, Germany, France, Spain, Mexico, Brazil and dozens of future markets are waiting. I DON'T THINK NOVO'S BIGGEST CHALLENGE WILL BE FINDING CUSTOMERS. I THINK IT COULD BE PRODUCING ENOUGH PILLS! The market is still treating Novo like a struggling obesity company. I see the possibility of an extraordinary global pharmaceutical growth story. $2.7 BILLION IN MONTHLY REVENUE FROM ONE ORAL PRODUCT BY DECEMBER 2027. That's my thesis. LET'S GO NOVO! 🇩🇰🚀 $NVO $LLY #Wegovy #NovoNordisk #GLP1 #Investing
3
4
1
88
6,349
Bitcoin’s biggest threat isn’t quantum computing. Not yet. It’s AI exposing the vulnerabilities of exchanges, hot wallets and custodians like Binance. Expect more sophisticated attacks, more theft and more loss of confidence. Banks won’t be immune either. The irony? In an AI-driven world, physical cash may become one of the most valuable forms of financial security. $BTC #Bitcoin #AI
2
487
🚨 $LLY FOUNDAYO: THE PHASE 3 RESULTS EVERY LILLY BULL SHOULD BE DISCUSSING! A direct question to @investseekers and @ObsvRetardation: WHERE IS YOUR ANALYSIS OF LILLY'S DISASTROUS JAPANESE PHASE 3 RESULTS? Published in The Lancet Diabetes & Endocrinology on October 30, 2026. And here's the extraordinary part: THE TRIAL WAS FUNDED BY ELI LILLY, AND FOUR OF THE EIGHT AUTHORS ARE LILLY EMPLOYEES AND SHAREHOLDERS! These aren't numbers invented by Novo investors. They're Lilly's own published clinical findings. 🇯🇵 FOUNDAYO — ATTAIN-J, 72 WEEKS: 🔴 Highest dose (36 mg): just 7.9% weight loss. 🔴 Lower dose (12 mg): 8.7%. The highest dose performed numerically WORSE! 🔴 33.3% discontinued treatment, compared with 15% on placebo. 🔴 Only 58.8% achieved at least 5% weight loss. 🔴 8% discontinued specifically because of nausea. Meanwhile, $NVO's oral semaglutide achieved 14.3% weight loss in OASIS 2, conducted in Japan and South Korea. Different trials, not head-to-head. @investseekers eagerly covers Foundayo's approval in China, US prescription growth and every positive Lilly headline. But where is the detailed coverage of this Japanese clinical study? And @ObsvRetardation, you're always ready to declare Novo's pipeline dead and celebrate Lilly's superiority. SO WHY AREN'T YOU DISCUSSING THESE RESULTS? Imagine the reaction if Novo had published a Phase 3 trial with 7.9% weight loss and one-third of patients discontinuing treatment at the highest dose. The criticism would be ENDLESS. But when it's Lilly? Apparently, a different standard applies. THIS IS THE LANCET. NOT A RUMOUR. NOT A BEARISH BLOG. LILLY'S OWN FUNDED RESEARCH. I'm genuinely interested in hearing how both of you interpret these findings. pubmed.ncbi.nlm.nih.gov/4296… $NVO $LLY #Foundayo #Wegovy @ObsvRetardation
3
2
18
1,291
Excellent post. But the full Lancet publication makes this even more concerning for $LLY. This isn't a rumour, a preliminary abstract or an analyst's interpretation. It's a peer-reviewed, Lilly-funded Phase 3 trial published in The Lancet Diabetes & Endocrinology on October 30, 2026. And the findings at the highest Foundayo dose are extraordinary: 🔴 Just 7.9% weight loss after 72 weeks. 🔴 33% discontinued treatment, versus 15% on placebo. 🔴 8% discontinued specifically because of nausea. 🔴 Only 58.8% achieved even 5% weight loss. 🔴 The 12 mg group actually achieved numerically GREATER weight loss than the 36 mg group: 8.7% vs 7.9%. And here's the remarkable part: FOUR OF THE EIGHT AUTHORS ARE LILLY EMPLOYEES AND SHAREHOLDERS. These are Lilly's own published clinical results! Yet where is the dedicated Lilly press release? Where is the extensive coverage from the analysts and commentators who enthusiastically promote every positive Foundayo headline? Imagine the reaction if $NVO had published these numbers. The double standard in investor communication deserves serious scrutiny. The Lancet, not a bearish opinion. Read the actual study. doi.org/10.1016/S2213-8587(2… $NVO $LLY
1
1
2
16
4,955
🚨 $NVO THIS IS HUGE. The full REDEFINE 9 paper is now published in The Lancet! I genuinely believe the market is underestimating what Novo Nordisk has achieved. Just 1.0 mg of semaglutide + 1.0 mg of cagrilintide, once weekly: ✅ 21.0% average weight loss! ✅ Almost HALF of patients lost at least 20% of their body weight! ✅ Just 4.9% discontinued because of adverse events — identical to placebo! And increasing both components to 1.7 mg produced 20.7% weight loss, with only 2.9% discontinuation due to adverse events. Yes, gastrointestinal side effects were common. But experiencing nausea is NOT the same as abandoning treatment. Patients largely stayed on therapy. Think about the implications: Only 1 mg of each active ingredient delivers approximately 21% weight loss. That creates potentially enormous opportunities for lower-dose treatment, manufacturing efficiency, pricing flexibility and global accessibility. The competitive implications for $LLY and Zepbound could be extraordinary. Novo doesn't need to invent a new obesity market. It already has the commercial infrastructure and now has published Phase 3 evidence of remarkable efficacy at low doses. And we haven't even seen the full commercial potential of CagriSema. This is the kind of science that can reshape an entire industry. $NVO $LLY
6
13
1
133
11,348
The irony of this post is extraordinary, @investseekers. You complain about $NVO's investor communication while promoting your own newsletter as the solution. But let's talk about the quality and balance of YOUR coverage. I've searched for your coverage of ATTAIN-J, Lilly's Japanese Phase 3 trial of Foundayo, published in The Lancet on October 30. I couldn't find it. Perhaps you can provide the link? Let's look at what investors deserve to know: 🔴 Foundayo 36 mg: just 7.9% weight loss after 72 weeks. 🔴 Foundayo 12 mg: 8.7%. The highest dose didn't even deliver better average results. 🔴 Only 58.8% of patients on 36 mg achieved at least 5% weight loss. 🔴 8% discontinued specifically because of nausea at the highest dose. These are published Phase 3 findings, not bearish speculation. Yet you find plenty of space to celebrate Foundayo's prescription growth, Chinese approval and supposed commercial momentum. Meanwhile, even when $NVO dominates US oral obesity prescriptions with 72.8% market share, your coverage quickly pivots to how Lilly is gaining ground. There's always a “however” when Novo delivers good news. And now you're suggesting investors should rely on your newsletter? Independent investor research requires balanced reporting, especially when the clinical data challenge the prevailing narrative. You don't need to be bullish on Novo. You need to apply the same scrutiny to Lilly. Before lecturing Novo about transparency, explain why such important Foundayo clinical results appear to be missing from your coverage. Investors deserve information, not selective narratives. $NVO $LLY
1
609
🚨 $LLY FOUNDAYO: DISASTROUS PHASE 3 RESULTS IN JAPAN. The numbers are brutal. Eli Lilly’s oral obesity drug is delivering roughly HALF the weight loss of $NVO’s oral semaglutide, while suffering massive treatment discontinuation at its highest dose. ATTAIN-J Phase 3 — 72 weeks, 36 mg: 🔴 Just 7.9% weight loss (treatment-regimen estimand). 🔴 33.3% discontinued treatment at the highest dose. ONE IN THREE patients! Versus 15% on placebo. 🔴 Only 58.8% achieved even 5% weight loss. 🔴 Increasing the dose from 12 mg to 36 mg actually produced WORSE average results: 8.7% vs 7.9%. Now compare that with $NVO’s oral semaglutide 50 mg in the East Asian OASIS 2 trial: 🟢 14.3% weight loss at 68 weeks. 🟢 84.3% achieved at least 5% weight loss. 🟢 Just 4.5% discontinued because of adverse events. These are separate trials, not a head-to-head comparison, but the contrast is extraordinary. Foundayo delivered only 55% of semaglutide’s reported weight-loss efficacy, despite using its highest tested dose. And the discontinuation numbers raise serious questions about long-term tolerability and commercial persistence. This is supposed to be Lilly’s next global oral obesity blockbuster? If these results are replicated across international populations, the commercial implications could be enormous. The narrative that Lilly will dominate the global oral obesity market deserves serious reconsideration. A major competitive warning for $LLY. A potentially significant opportunity for $NVO. $NVO $LLY $VKTX
22
24
13
233
62,630
Everyone should be paying attention to semaglutide. 2026 studies found 12% longer median lifespan in female mice and slower epigenetic aging markers in humans. I feel the difference myself: I go running, don't drink alcohol, and my liver-area pain has disappeared. Semaglutide could be much more than a weight-loss drug. $NVO
3
7
757
FollowTheFilings retweeted
People dont realize when your competitor becomes a generic then so do you.
1
1
47
FollowTheFilings retweeted
Capture adjusted IQVIA, week ending 30 Oct: - Wegovy pill: app. 296,000 weekly TRx (183,500 reported, 62% capture) - Foundayo: app. 72,000 (65,000 reported, 90%) Novo has 4x the volume. But since Medicare coverage both have added around 50k weekly scripts $NVO $LLY
4
3
4
25
10,815
The fundamental mistake in AI revenue projections is assuming that one side of the economic equation remains unchanged. AI eliminates jobs, salaries, operating costs and entire layers of intermediate demand. At the same time, automated companies can slash prices because they no longer need the same human resources. And people claim lower prices will create more demand. From whom? Who will have the income to buy those products? Lower prices do not create purchasing power. If AI replaces millions of workers, it also destroys the income that supports consumption. The result could be massive deflation, unemployment and collapsing nominal revenues. You cannot project trillions in future AI revenues using today's economic structure when the technology itself is supposed to dismantle that structure. The more successful AI becomes at eliminating costs, the more it risks destroying the very revenue base needed to justify its valuations.
1
312
FollowTheFilings retweeted
🇸🇪 @Swedbank reiterates BUY on $NVO with a DKK 335 price target. Their investment case is interesting: • Oral Wegovy is gaining traction internationally and in US direct-to-consumer channels. • Wegovy’s market share by volume has stabilised. • International obesity markets are growing >30%. • Wegovy 7.2 mg could support injectable growth. • CagriSema approval in Q4 could be a major catalyst for 2027. The risks remain: US net pricing pressure and semaglutide patent expiries, particularly in Canada. But Swedbank sees Novo’s constant-currency sales growth improving from -1% in 2026 to +5% in 2027 and +9% in 2028. Notably, their 2028 growth estimate is well above market consensus of just 3%. Their view: Novo’s growth potential is still being underestimated. $NVO #NovoNordisk Source: swedbank-aktiellt.se/analyse…
3
2
26
1,612
🚨 $NVO — THE MARKET IS MISSING THE BIGGER PICTURE. This is a marathon, not a sprint. And Symphony Health's prescription data suggests we may be witnessing the birth of an entirely new pharmaceutical paradigm. Let's look at the numbers. 📊 SYMPHONY HEALTH — U.S. WEEKLY PRESCRIPTIONS Wegovy oral: • Week 27: 119,347 • Week 35: 144,431 • Week 42: 217,050 That's +81.9% in just 15 weeks! Meanwhile, $LLY's Foundayo recorded only 29,155 prescriptions in week 42. Wegovy oral is outselling Foundayo by 7.4 to 1 in Symphony's prescription dataset. And these figures exclude significant online pharmacy and telehealth channels. 💰 NOW LET'S PROJECT 2027. Novo already reported DKK 3.22B in Wegovy oral sales in Q2 2026, before meaningful international expansion. Using Symphony's U.S. prescription trajectory as our volume reference, my 2027 scenario assumes: • U.S. Wegovy oral revenue: $5.9B • International revenue: $2.96B (50% of U.S.) • Global Wegovy oral revenue: $8.86B At EUR/USD 1.09 and EUR/DKK 7.46, that represents approximately DKK 60.6B. Now consider Novo Nordisk's entire business. 2025 actual revenue: DKK 309.1B. Assume every other business grows just 5% cumulatively by 2027, with oral Wegovy providing incremental revenue. 2027 projected total: DKK 385.2B. 🚀 THAT'S +24.6% REVENUE GROWTH IN DKK VERSUS 2025. And this scenario doesn't require explosive growth from Ozempic, injectable Wegovy or the rest of Novo's portfolio. It does require continued prescription growth, international adoption and successful monetization. This is my scenario, not company guidance. This is why I'm looking beyond quarterly market-share headlines. We may be witnessing the beginning of a completely new paradigm in obesity treatment, with extraordinary commercial potential. Nobody knows how big this market can ultimately become. The marathon has barely begun. $NVO $LLY
9
434
FollowTheFilings retweeted
$NVO vs $LLY – Interesting tolerability data! 💊 UBT251: Only 1 of 155 patients (0.6%) discontinued due to adverse events over 24 weeks. 💊 Retatrutide: 6–16% discontinued due to adverse events over 48 weeks. ⚠️ Different trials and durations, so not a head-to-head comparison.
🤖 Made with AI
5
6
45
4,207
The growing nervousness among $LLY bulls is becoming increasingly obvious. Now they're openly complaining about LillyDirect, prescription delays, customer acquisition friction and lost sales opportunities. And yet the market continues to value Lilly as if its competitive dominance were virtually guaranteed. Look at the valuations: $LLY: $1.14 TRILLION market cap. ~33x forward earnings. $NVO: $172 BILLION market cap. ~12x forward earnings. Almost THREE TIMES the earnings multiple! Meanwhile, Novo already has oral Wegovy, Wegovy HD, CagriSema approaching a regulatory decision, and an expanding next-generation pipeline. The problem isn't that Lilly is a bad company. It's that its valuation leaves very little room for competitive surprises. And Novo is delivering precisely those surprises. This valuation gap is becoming increasingly difficult to justify. The more defensive Lilly bulls become, the more obvious the risk of a major market repricing. $NVO $LLY
5
400
These numbers deserve MUCH more attention. CagriSema 2.4/2.4 mg vs Zepbound 15 mg in WOMEN: Premenopausal: CagriSema 26.7% vs Zepbound 26% Perimenopausal: CagriSema 24.8% vs Zepbound 23% Postmenopausal: CagriSema 23.1% vs Zepbound 23% Overall female analyses: CagriSema 25% vs Zepbound approximately 25%. Different clinical trials, not a head-to-head comparison, but the numerical results are remarkable. And remember: CagriSema achieves these results with just 2.4 mg of semaglutide plus 2.4 mg of cagrilintide. You don't have to prove superiority over Lilly to recognize the enormous commercial opportunity here. The real question is how much market expansion Novo can unlock with effective pricing and sufficient manufacturing capacity. $NVO $LLY
6
331
Here's what I think $NVO bears are completely missing. Novo will launch CagriSema at $150/month. Think about the implications. Wegovy HD requires 7.2 mg of semaglutide weekly to deliver 20.7% weight loss. CagriSema combines just 2.4 mg of semaglutide with 2.4 mg of cagrilintide and delivered 22.7% overall weight loss, reaching 25% in women. One-third of the semaglutide dose. A second mechanism of action. Exceptional clinical efficacy. The manufacturing economics deserve far more attention than they are getting. At $150/month, the addressable market could explode. Millions of patients who have a prescription but cannot afford treatment could suddenly enter the market. That is how you transform an entire industry: not by fighting endlessly over existing customers, but by making treatment accessible to millions more. And Wall Street is still debating whether CagriSema can steal a few patients from Zepbound. They're looking at the wrong opportunity. $NVO $LLY
3
3
320
FollowTheFilings retweeted
Novo's experimental CagriSema injection showed 25% weight loss in women in a late-stage trial. The company said it could also improve weight loss beyond its blockbuster GLP-1, Wegovy. $NVO
2
1
19
1,086
$NVO — CagriSema 2.4/2.4 mg at $125/month after FDA approval could completely transform the obesity market. And it would fit Novo's announced 2027 price reduction strategy. Wall Street is looking at this market COMPLETELY WRONG. REDEFINE 4: CagriSema: 23% weight loss. Zepbound 15 mg: 25.5%. Zepbound's regular self-pay price: $699/month. At $125, CagriSema will be 82% cheaper for just 2.5 percentage points less weight loss. But THE REAL STORY ISN'T EFFICACY ANYMORE. IT'S PRICE, VOLUME AND INDUSTRIAL EFFICIENCY. According to IQVIA, only 35 out of 100 new obesity prescriptions in the commercially insured market are actually filled. The patients exist. The prescriptions exist. But affordability and insurance restrictions prevent millions of treatments from starting. Imagine recovering those patients with a $125/month treatment. Now consider the manufacturing advantage. CagriSema 2.4/2.4 uses THREE TIMES LESS semaglutide than Wegovy HD 7.2 mg. And Novo has already demonstrated 21% weight loss with CagriSema 1/1 mg in another trial. Just ONE milligram of semaglutide weekly! NOW THINK ABOUT GENERICS. This is what analysts seem to be completely missing in their 4-year valuation models. They assume semaglutide patent expiration means inevitable price destruction and declining $NVO profitability. But generic manufacturers cannot simply copy CagriSema's patented combination. To compete with its efficacy using semaglutide alone, they could need substantially higher doses, enormous API production capacity and considerable industrial investment. Meanwhile, Novo estimates US patent protection for CagriSema until 2039. GENERIC COMPETITION IS NOT JUST ABOUT PATENT EXPIRATION. IT'S ABOUT MANUFACTURING CAPACITY, COST PER PATIENT AND PRODUCT DIFFERENTIATION. What if Novo can treat several times more patients with the same semaglutide capacity while cutting prices dramatically? What if its next growth phase comes from converting millions of abandoned prescriptions into actual treatments? And what if a future low-cost CagriSema 1/1 mg makes this advantage even greater? Analysts are valuing Novo four years ahead while obsessing over a 2.5-point efficacy difference and the semaglutide patent cliff. They're overlooking the possibility that Novo could transform its entire business model before that cliff arrives. Lower prices. Millions more patients. Greater manufacturing efficiency. A differentiated product protected well beyond semaglutide's expected patent expiration. CAGRiSEMA COULD BE NOVO'S DEFENCE AGAINST GENERICS AND ITS BIGGEST GROWTH OPPORTUNITY. THE NEXT OBESITY MARKET BATTLE WILL BE WON THROUGH VOLUME, ACCESS AND INDUSTRIAL SCALE. Not by another 2% of weight loss. $NVO $LLY
1
10
321
Wall Street is missing the real CagriSema story. And I believe it could completely change the investment thesis for $NVO. Everyone is obsessed with maximum weight loss percentages. Who gets 23%, 25% or 27%? Wrong question. The real question is: HOW MUCH semaglutide do you need to achieve approximately 20% weight loss? Look at Novo Nordisk's own clinical results: CagriSema 1 mg/1 mg: 21% weight loss. Wegovy HD 7.2 mg: 20.7% weight loss. Different trials, different durations, not a head-to-head comparison. But the difference in semaglutide consumption is extraordinary. CagriSema delivers approximately 20% weight loss using just ONE milligram of semaglutide, combined with 1 mg of cagrilintide. Now think about manufacturing economics. To supply 10 million patients for one year at those weekly doses: CagriSema requires 520 kg of semaglutide. Wegovy HD requires 3,744 kg. At 100 million patients: CagriSema: 5.2 metric tonnes. Wegovy HD: 37.44 metric tonnes. That is a 7.2x difference in semaglutide API requirements. And THIS is where the generic competition story becomes very interesting. Analysts keep discussing semaglutide patent expiration as if generic manufacturers could simply enter the market, slash prices and destroy Novo's economics. But who is going to manufacture the quantities required to serve tens of millions of patients? A generic manufacturer attempting to replicate approximately 20% weight loss using high-dose semaglutide alone faces vastly greater semaglutide production requirements than Novo would with CagriSema 1/1 mg. That means manufacturing capacity, capital investment, production costs and supply-chain execution. CagriSema also requires cagrilintide, so the total manufacturing cost advantage is not yet established. But the semaglutide capacity advantage is impossible to ignore. And there is another critical point. Novo estimates US semaglutide patent expiration in 2032. CagriSema's estimated patent protection extends to 2037. A differentiated, patent-protected combination that potentially allows Novo to treat dramatically more patients using the same semaglutide production capacity. Think about it. The obesity market is still in its infancy. Hundreds of millions of people worldwide could eventually need treatment, and many will require long-term maintenance. The winner will not necessarily be the company achieving the highest percentage of weight loss in a clinical trial. It could be the company capable of delivering clinically meaningful weight loss to the greatest number of patients at the lowest sustainable cost, with a defensible intellectual-property position. In my view, CagriSema could be Novo Nordisk's lifeline. Not because it wins every maximum-dose efficacy comparison. Because it potentially changes the entire economics of semaglutide treatment and creates a formidable industrial barrier against generic competition. Wall Street is still treating CagriSema as a weight-loss percentage story. I think it is a manufacturing scale, API efficiency and patent protection story. And that distinction could be worth billions. $NVO $LLY
1
1
13
288